Cargando…

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study

BACKGROUND: Intravenous (IV) ketamine and intranasal (IN) esketamine have been studied as novel alternatives to manage treatment-resistant depression (TRD). The objective of this observational pilot study is to compare the real-world effectiveness and tolerability of IV ketamine and IN esketamine in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gutierrez, Gilmar, Rosenblat, Joshua, Hawken, Emily, Swainson, Jennifer, Vazquez, Gustavo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2022
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171596/ https://www.ncbi.nlm.nih.gov/pubmed/35604752 http://dx.doi.org/10.2196/34711

Ejemplares similares

Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
por: Vazquez, Gustavo, et al.
Publicado: (2022)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis
por: Chen, Cheng-Chuan, et al.
Publicado: (2023)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
por: Keeler, Johanna Louise, et al.
Publicado: (2023)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Letter]
por: Manu, Lucian
Publicado: (2023)

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
por: Wilkowska, Alina, et al.
Publicado: (2021)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Response to Letter]
por: Chen, Cheng-Chuan, et al.
Publicado: (2023)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
por: Skala, Katrin, et al.
Publicado: (2023)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
por: Capuzzi, Enrico, et al.
Publicado: (2021)

Intranasal esketamine use in bipolar disorder: A case report
por: Skriptshak, Courtney, et al.
Publicado: (2021)

Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
por: Jollant, Fabrice, et al.
Publicado: (2023)

Esketamine Anesthetizes Mice With a Similar Potency to Racemic Ketamine
por: Ma, Xiaofan, et al.
Publicado: (2023)

A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential
por: Chubbs, Brittany, et al.
Publicado: (2022)

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
por: Correia-Melo, Fernanda S., et al.
Publicado: (2018)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
por: Vázquez, Gustavo H., et al.
Publicado: (2021)

Esketamine may be an ideal substitute for ketamine during cochlear function measurement
por: Li, Yufeng, et al.
Publicado: (2021)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
por: Olivola, Miriam, et al.
Publicado: (2022)

Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management
por: Yip, Ryan, et al.
Publicado: (2022)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Median effective dose of esketamine for intranasal premedication in children with congenital heart disease
por: Huang, Jiajia, et al.
Publicado: (2023)

Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants
por: Pfiffner, Miriam, et al.
Publicado: (2023)

The analgesic effect of combined treatment with intranasal S-ketamine and intranasal midazolam compared with morphine patient-controlled analgesia in spinal surgery patients: a pilot study
por: Riediger, Christine, et al.
Publicado: (2015)

A comparison of intranasal ketamine and intranasal midazolam for pediatric premedication
por: Narendra, P. L., et al.
Publicado: (2015)

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2021)

A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial
por: Lu, Xinlei, et al.
Publicado: (2022)

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
por: Rothärmel, Maud, et al.
Publicado: (2022)

Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth
por: Chisamore, Noah, et al.
Publicado: (2023)

Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs
por: Vlerick, Lise, et al.
Publicado: (2020)

Comparative Study of Intranasal Dexmedetomidine Versus Intranasal Ketamine as Premedicant in Children
por: Arun, Nidhi, et al.
Publicado: (2022)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fhpht1dd4jv4ql6mbi4itr59tp